medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2002, Number 2

<< Back Next >>

Rev Biomed 2002; 13 (2)

Enfermedades infecciosas endémicas, emergentes y reemergentes en Yucatán a principios del Siglo XXI

Góngora-Biachi RA, Castro-Sansores CJ, González-Martínez P, Ayora-Talavera G, Loroño-Pino MA, Farfán-Ale JA

Language: Spanish
References: 59
Page: 130-143
PDF size: 65.30 Kb.


Text Extraction

No abstract


REFERENCES

  1. Lederberg J. Emerging Infection: an evolutionary perspective. Emerg Infect Dis 1998; 4:366-71.

  2. Góngora-Biachi RA, Castro-Sansores C, Pérez-Carrillo H, González-Losa MR, Rodríguez-Angulo E, Farfán-Ale JA, et al. Enfermedades emergentes y reemergentes en Yucatán a finales del siglo XX. Rev Biomed 1997; 8:247-65.

  3. Fauci AS. New and reemerging diseases: the importance of biomedical research. Emerg Infect Dis 1998; 4:374-8.

  4. Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis 1995; 1:1-12.

  5. Góngora-Biachi RA, González-Martínez P. La dinámica epidemiológica de la infección por el VIH-1 en Yucatán (1983-1989). Rev Biomed 1990; 1:53-60.

  6. Góngora-Biachi RA, González-Martínez P. Anticuerpos contra el virus de Inmunodeficiencia humana (VIH) en una población de prostitutas de Mérida, Yucatán, México. Rev Invest Clin 1987;39:305-6.

  7. Góngora-Biachi RA, Valadez-González N, Castro- Sansores C, Guerrero-Flore A, Vera-Gamboa L. V Simposio de Actualización: SIDA 2000. Rev Biomed 2001; 12:47-62.

  8. Góngora-Biachi RA, Lal RB, Rudolph DL, Castro-Sansores C, González-Martínez P, Pavía-Ruz N. Low prevalence of HTLV-II in mayan indians in the Yucatán Peninsula, México. Arch Med Res 1997; 28:555-8.

  9. Góngora-Biachi RA, González-Martínez P, Puerto FI, Sosa-Muñoz J, Duarte-Zapata L, Bastarrachea-Ortiz J, et al. A low prevalence of HTLV-I/II infection among eight population groups from Mérida, Yucatan, Mexico. J Acq Immun Def Synd 1992; 5:104-6.

  10. Gongora-Biachi RA, Gonzalez-Martinez P, Castro- Sansores C, Pavia-Ruz, Rudolph DL, Lal RB. Human T Lymphotropic Virus type II (HTLV-II) infection among female prostitutes in Yucatan Mexico. Am J Med Sci 1993; 306:207-11.

  11. González-Martínez P, Castro-Sansores C, Vivas- Rosel ML, Góngora-Biachi RA. Infección por el virus linfotrópico de células T humanas tipo I/II en pacientes poli transfundidos en el estado de Yucatán, México. Sangre 1994; 39:45-8.

  12. Lal RB, Góngora-Biachi RA, Pardi D, Swizer WM, Goldman I, Lal AA. Evidence for mother-to-child transmission of Human T Lymphotropic Virus type II. J Infect Dis 1993; 168:586-91.

  13. Hayes CG. West Nile Virus: Uganda, 1937, to New York City, 1999. Ann N Y Acad Scien 2001; 951: 25-37.

  14. Secretaría de Salud. Estadísticas. http://www.ssa.gob.mx.

  15. N'galy B, Ryder RW. Epidemiology of HIV infection in Africa. J Adquir Inmune Defic Syndr 1988;1:551-8.

  16. Report on the global HIV/AIDS epidemic-June 2001 http://www.unaids.org/epidemic_update/report_dec01/index.html.

  17. Hjelle B. Human T-cell leukemia/lymphoma viruses: Life cycle, pathogenicity, epidemiology and diagnosis. Arch Pathol Lab Med 1991; 115: 440-50.

  18. Manns A, Blattner WA. The epidemiology of human T-cell lymphotropic virus type I and type II: etiologic role in human disease. Transfusion 1991; 31: 67-75.

  19. Góngora-Biachi RA, González-Martínez P, Puerto FI, Pavía-Ruz N, Baeza-Bacab M. Primer caso en México de infección por el virus linfotrópico de células T humanas asociado a transfusión sanguínea en una niña. Rev Invest Clin 1991; 43:399-400.

  20. Yamaguchi K, Kiyokawa T, Futami G, Ishii T, Takatsuki K. Patogénesis of adult T-cell leukemia from clinical pathology features. In: Blattner W, ed. Human Retrovirology: HTLV. New York. Raven Press; 1990. p. 163-71.

  21. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986: 1:1031-2.

  22. Zehender G, De Maddalena C, Osio M, Cavalli B, Parravicini C, Moroni M, et al. High prevalence of human T cell lymphotropic virus type II infection in patients affected by human immunodeficiency virus type 1—associated predominantly sensory polyneuropathy. .J Infect Dis 1995; 172: 1595-8.

  23. Hjelle B, Mills R, Swenson S, Mertz G, Key C, Allen S. Incidence of hairy cell leukaemia, mycosis fungoide and chronic lymphocytic leukaemia in first know HTLVII- endemic population. J Infect Dis 1991; 163:435-40.

  24. Kaplan MH, Sadick NS, McNutt NS, Talmor M, Coronesi M, Hall WW. Acquired ichthyosis in concomitant HIV-1 and HTLV-II infection: a new association with intravenous drug abuse. J Am Acad Dermatol 1993; 29:701-8.

  25. Defreitas E, Hilliard B, Cheney P, Bell DS, Kiggundu E, Sankey D, et al. Retroviral sequences related to human T-Lymphotropic virus type II in patients with chronic fatigue immune dysfunciones syndrome. Proc Natl Acad Sci USA 1991; 88:2922-6.

  26. Yokoi K, Kawai H, Akaike M, Mine H, Saito S. Presence of human T-lymphotropic virus type II-related genes in DNA of peripheral leukocytes from patients with autoimmune thyroid diseases. J Med Virol. 1995; 45:392-8.

  27. Poiesz B, Dube D, Dube S, Love J, Papsidero L, Uner A, et al. HTLV-II-associated cutaneous T-cell lymphoma in a patient with HIV-1 infection. N Engl J Med 2000; 342:930-6.

  28. Stamboulian D, Bonvehi PE, Nacinovich FM, Cox NJ. Influenza. Infect Dis Clin NA 2000; 14:141-66.

  29. Cox N., Subbarao K. Global epidemiology ofinfluenza: Past and present. Ann Rev Med 2000; pp 407-18.

  30. Nguyen Van Tam JS. Epidemiology of influenza. En: Nicholson KG., Webster RG., Hay AJ, editor. Textbook of influenza. . Oxford :Blackwell Science Ltd.; 1998. p.181-206.

  31. Leese J, Tamblyn SE. Pandemic planning. En: Nicholson KG., Webster RG., Hay AJ, editors. Textbook of influenza. Oxford:Blackwell Science Ltd ;1998. p. 551-9.

  32. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradly DW, Hougton M. Isolation of a DNA clone derived from a blood borne non-A non-B viral hepatitis genome. Science 1989; 244: 359-362.

  33. Pozzato G, Kaneko S, Moretti M, Croce Ls, Franzin F, Unoura M. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. J Med Virol 1994; 43: 291-296.

  34. Amarapurkar D. Natural history of hepatitis C virus infection. J Gastroenterol Hepatol 2000; 15: S105-S110.

  35. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of Hepatitis C. Ann Intern Med 2000; 132: 296-305.

  36. Góngora-Biachi RA, González-Martínez P, Puerto FI, Yamaguchi K, Nishimura Y, Takatsuky K. Antibodies to hepatitis C virus in people from Yucatán, México. Rev Invest Clin 1992; 44: 284.

  37. Alberti A, Chemello L, Benvegnù. Natural history of hepatitis C. J Hepatol 1999; 31: (Supp.1) 17-24.

  38. Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol 1999; 31: (Supp.1) 25-30.

  39. Heathcote EJ, Shiffman ML, Cooksley GE, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2001; 343: 1673-80.

  40. Baffis V, Shrier I, Sherker AH, Szilagyi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or C virus infection. Ann Intern Med 1999; 131: 696-701.

  41. Craven R and Roehrig JT. West Nile Virus. JAMA 2001; 28:651-3.

  42. Lanciotti RS, Roehrig JT, Deubel V, Smith J, Parker M, Steele K, et al. Origin of the West Nile Virus responsible for an outbreak of encephalitis in the Northeastern United States. Science 1999; 286:2333-7.

  43. http://www.cdc.gov/ncidod/dvbid/westnile/q&a.htm

  44. Nash D, Mostashari F, Fine A, Miller J, O´Leary D, Murray K, et al. The outbreak of West Nile Virus infection in the New York city area in 1999. N Engl J Med 2001; 344:1807-14.

  45. Centers for Disease Control and Prevention. Epidemic/Epizootic West Nile Virus in the United States: Revised Guidelines for surveillance, prevention, and control. U.S. Dept of Health and Human Services, CDC Fort Collins, Colorado, 2001.

  46. Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol , 1990; 44: 649-88.

  47. Henchal EA, Putnak JR. The dengue viruses. Clin Microbiol Rev 1990; 3:1376-96.

  48. Gubler DJ, Clark GG. Dengue/dengue hemorrhagic fever: The emergence of a global problem. Emerg Infect Dis 1995; 1:55-7.

  49. Monath TP. Dengue: the risk to developed and developing countries. Proc Natl Acad Sci USA 1994; 91:2395-400.

  50. Farfán-Ale JA, Loroño-Pino MA. Incidencia de infección por virus dengue en niños de 8 a 14 anos de edad radicados en las áreas urbana y rural del municipio de Mérida, Yucatán. Bol Med Hosp Infant Mex 1991; 48:780-4.

  51. Loroño- Pino MA, Farfán-Ale JA, Rosado-Paredes EP, Kuno G, Gubler DJ. Epidemic dengue 4 in the Yucatan, Mexico, 1984. Rev Inst Med Trop Sao Paulo 1993; 35:449-55.

  52. Holland J, Spindler K, Horodysky F, Grabav E, Nichol S, Vanderpol S. Rapid evolution of RNA genomes. Science 1982; 215: 735-44.

  53. Holland J. (1984) Continuum of change in RNA virus genomes. In Notkins AL, Oldstone MBA, Editors. "Concepts in Viral Pathogenesis". New York:Springer-Verlag; 1984. pp. 137-43.

  54. Steinhauer DA, Holland JJ. Rapid evolution of RNA viruses. Annu. Rev Microbiol 1987; 41: 409-33.

  55. Steinhauer D A, Domingo E, Holland J J. Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene 1992;122: 281-8.

  56. Smith D B, Inglis S C. The mutation rate and variability of eukaryotic viruses: an analytical review. J Gen Virol 1987; 68: 2729-40.

  57. Domingo E. RNA virus evolution and the control of viral disease. Prog Drug Res 1989; 33: 93-133.

  58. Holmes E C, Worobey M, Rambaut A. Phylogenetic evidence for recombination in dengue virus. Mol Biol Evol. 1999; 16 : 405-9.

  59. Farfan JA, Olson K E, Black W C, Gubler DJ, Beaty BJ. Rapid characterization of genetic diversity among twelve dengue-2 virus isolates by single-strand conformation polymorphism analysis. Am J Trop Med Hyg 1997; 57:416-22.




2020     |     www.medigraphic.com